Veru is racing its balance sheet to prove enobosarm can turn GLP-1 weight loss from smaller bodies into stronger, healthier bodies.
Overview
Veru is a high-risk, high-upside biotech at a pivotal inflection point. The company has cut losses, sold legacy assets, improved cash to $27.6 million, and focused resources on enobosarm for GLP-1-associated muscle loss and weight-loss plateau. Phase 2b QUALITY data showed compelling lean-mass preservation and functional benefits, while the PLATEAU trial could validate enobosarm as a metabolic-restorative adjunct. However, going-concern language, dilution risk, and dependence on 2027 clinical catalysts make the investment binary.